Selected article for: "clinical case and potential effect"
Author: Takayama-Ito, Mutsuyo; Saijo, Masayuki
Title: Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection
  • Document date: 2020_2_11
    • ID: 0czu600e_28
    Snippet: CCBs, which are used to control cardiovascular diseases, have demonstrated significant effects against SFTSV replication both in vitro and in vivo . Notably, retrospectively conducted clinical study suggested that nifedipine remarkably reduced the case fatality rate in SFTS patients . Although nifedipine is administrated consistently for patients with cardiac disease, these findings are valuable for developing potential CCB-based therapeutics for.....
    Document: CCBs, which are used to control cardiovascular diseases, have demonstrated significant effects against SFTSV replication both in vitro and in vivo . Notably, retrospectively conducted clinical study suggested that nifedipine remarkably reduced the case fatality rate in SFTS patients . Although nifedipine is administrated consistently for patients with cardiac disease, these findings are valuable for developing potential CCB-based therapeutics for SFTS. It is considered that the efficacy of nifedipine in treating patients with SFTS should be evaluated in a prospective manner. For clinical use, careful consideration of the risk-to-benefit value to the patient would be required because an overdose of CCBs has a high-risk of side effects, such as edema, liver damage, and death. The dose used for in vivo mouse study (100 mg/kg/day) was extremely higher than the dose generally used for humans (∼0.2-1.5 mg/kg/day). Still, these findings indicated the potential therapeutic effect of CCB treatment in patients with SFTS.

    Search related documents:
    Co phrase search for related documents
    • benefit risk and cardiovascular disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • benefit risk and careful consideration: 1, 2, 3, 4, 5
    • benefit risk and clinical study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • benefit risk and fatality rate: 1, 2, 3, 4
    • benefit risk and kg mg day: 1, 2, 3, 4, 5
    • benefit risk and patient treat: 1
    • benefit risk and significant effect: 1, 2, 3
    • benefit risk and therapeutic effect: 1, 2
    • benefit risk value and clinical study: 1
    • cardiac disease and careful consideration: 1
    • cardiac disease and clinical study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
    • cardiac disease and fatality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • cardiac disease and kg mg day: 1, 2, 3, 4
    • cardiac disease and significant effect: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • cardiac disease and therapeutic effect: 1, 2